New antibody shot shows promise for eczema in early trial
NCT ID NCT05114889
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental antibody injection called BSI-045B in 54 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check safety and tolerability, with some early looks at how well it might control symptoms. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BSI-045B (an antibody injection)
What this could lead to
If successful, this could point toward a new treatment option for atopic dermatitis (eczema) that reduces symptoms like itching and skin inflammation.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. It is small (54 participants) and may not lead to a proven treatment. Side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia